Innate Pharma S.A.

NASDAQ:IPHA

Biotechnology

Healthcare
$0.94 +1.91%

+$0.03 today

Market cap
$104.99M
Beta
0.89
P/E (TTM)
-3.0
EPS (TTM)
-$0.54
52W Low $1.17High $2.63

Volume 0.06M

Average 0.07M

IPHA Deferred Income Tax

The difference between tax expense recognized and tax actually paid in cash during the period.

Innate Pharma S.A.NASDAQ: IPHA

{ "id": "headlineOutflowGrows", "params": { "amount": { "type": "amount", "value": 0 } } }

[ { "id": "valueVsYearAgo", "params": { "period": { "type": "period", "period": { "kind": "quarter", "fiscalYear": 2025, "fiscalQuarter": 4 } }, "amount": { "type": "amount", "value": 0 }, "previous": { "type": "amount", "value": 0 } } } ]

Context

  • { "id": "shareOfRevenueUnchanged", "params": { "share": { "type": "share", "value": 0 }, "period": { "type": "period", "period": { "kind": "fiscalYear", "fiscalYear": 2025 } } } }
  • { "id": "streakIncreased", "params": { "rises": { "type": "count", "value": 0 }, "years": { "type": "count", "value": 3 } }, "count": 3 }
  • { "id": "extremeHighestFigure", "params": { "fiscalYear": { "type": "fiscalYear", "value": 2025 }, "years": { "type": "count", "value": 4 } } }

Sources:Cash FlowText generated from reported figures; not investment advice.

Dec 2025
€0—
Dec 2025
€0—
Deferred Income Tax past and forecast growth by horizon
Horizon Past Forecast Difference
———
———
———
——
——

Deferred Income Tax history

EUR · from the cash flow

Latest · FY2025
0 EUR
Year-over-year change
—

Deferred Income Tax vs competitors

How IPHA compares with its peers on the latest reported figures

  • { "id": "currencyMixedRevenue", "params": {} }
  • { "id": "shareOfRevenueMedian", "params": { "ticker": { "type": "text", "value": "IPHA" }, "share": { "type": "share", "value": 0 }, "median": { "type": "share", "value": 0 } } }
IPHA Competitors
Deferred Income Tax for IPHA and competitors
Company Period YoY 3-year CAGR
IPHAInnate Pharma S.A.—€0 EUR——
NVCTNuvectis Pharma, Inc.—$0 USD——
CGENCompugen Ltd.—$0 USD——
MOLNMolecular Partners AG—CHF 0 CHF+100.0%—
CRBPCorbus Pharmaceuticals Holdings, Inc.—$0 USD——
MISTMilestone Pharmaceuticals Inc.—$0 USD——
CRDFCardiff Oncology, Inc.—$0 USD——
RANIRani Therapeutics Holdings, Inc.—$0 USD——
ELTXElicio Therapeutics, Inc.—$0 USD-100.0%—
Peer median (excluding IPHA) —+0.0%—

Competitors are the stored peer set for IPHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Net Income(52.81M)(58.1M)(7.57M)(49.47M)(49.18M)
Depreciation & Amortization4.6M45.41M5.09M1.99M5.09M
Deferred Income Tax(1.68M)0000
Stock-Based Compensation2.62M4.25M4.26M3.94M4.26M
Change in Working Capital(9.88M)(12.5M)(32.09M)39.16M(10.21M)
Accounts Receivables3.39M(4.2M)(13.67M)00
Inventory(6.27M)0000
Accounts Payables(946K)(7.66M)(3.89M)00
Other Working Capital(6.06M)(636K)(10.54M)39.16M(10.21M)
Other Non-Cash Items(1.3M)1.8M(2.24M)(2.53M)(630.52K)
Operating Cash Flow(58.46M)(19.15M)(32.56M)(6.9M)(50.67M)
Capital Expenditures(1.33M)(1.12M)(2.35M)(391K)(134.47K)
Acquisitions (Net)7K0004.8K
Purchases of Investments00000
Sales of Investments03M22.77M9.59M13.51M
Other Investing Activities406K(1K)(1.79M)1K(6.38M)
Investing Cash Flow(917K)1.88M20.63M9.2M7M
Debt Repayment26.63M(2.03M)(2.36M)(8.94M)(8.56M)
Common Stock Issued499K198K395K2.93M14.39M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities187K198K395K2.93M0
Financing Cash Flow26.82M(1.83M)(1.97M)(6.01M)5.83M
Effect of Forex Changes(483K)(428K)274K(505K)7.41M
Net Change in Cash(33.04M)(19.53M)(13.62M)(4.21M)(30.44M)
Free Cash Flow(59.79M)(20.28M)(34.91M)(7.29M)(50.81M)

Innate Pharma S.A.

NASDAQ:IPHA

Intrinsic Alpha fair value

Locked

Current Price

$0.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.